A randomized, double-blind, parallel-group trial comparing bicalutamide (Casodex) 150mg once daily with placebo in patients with non-metastatic prostate cancer

Trial Profile

A randomized, double-blind, parallel-group trial comparing bicalutamide (Casodex) 150mg once daily with placebo in patients with non-metastatic prostate cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Bicalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CAPRI
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jan 2009 Acronym identified as CAPRI, reported by Clinicaltrials.gov.
    • 07 Jan 2009 Actual end date reported as October 2008 by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top